At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 313 enrolled
Drug / intervention
Usual Care +1 moredrug
Likely dose
Dalbavancin 1500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pragmatic Trial Designed to Evaluate a New Critical Pathway for Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections
In Brief
A Phase 4 clinical trial evaluating Usual Care and Dalbavancin for Acute Bacterial Skin and Skin Structure Infections. Completed, enrolled 313 participants across 11 sites.
Detailed Summary
This study will evaluate a new critical pathway (use of guideline-based patient identification criteria and for those who meet these criteria, use of dalbavancin) for the treatment of ABSSSI compared to usual care.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 2016
Enrollment StartNov 2016
Primary CompletionMar 2019
TodayJul 2026
First PostedNov 11, 2016
Enrollment StartNov 29, 2016
Primary CompletionMar 29, 2019
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 9.6 years ago
Interventions
Usual Caredrug
Usual care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
Dalbavancindrug
Dalbavancin administered as a single IV dose of 1500 mg over 30 minutes.